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Hypertension poses a huge financial risk to any funder/
medical aid, including the risk-mitigating strategies 
provided by the managed care organisations that are 
required to manage patients with hypertension. According 
to the annual report of the South African Council for 
Medical Schemes for 2010 - 2011, which was published on 6 September 
2011,[1] hypertension is the most prevalent chronic disease among medical 
aid members, 11.7% of whom have this condition. Considering that the 
medical aid industry has 8 315 718 beneficiaries,[2] 972 940 members will 
therefore require treatment for hypertension. In terms of the medical aid 
membership on which this research article is based, the membership is 
483 379 and the hypertension prevalence is 28 875 beneficiaries.[3] 
The most up-to-date South African Hypertension Guideline[4] 
includes a consensus statement on the use of angiotensin converting 
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) 
for the management of hypertension, stating that the choice of therapy 
for either an ACEI or an ARB should be based on cost and tolerability. 
Objective
To assess the costs of ACEIs v. ARBs in the management of hypertensive 
patients and the prevention of cardiovascular complications for a 
private medical aid scheme in South Africa (SA).
Method
A Phase IV observational, retrospective (2010 and 2011), cohort 
study was undertaken involving over 480  000 beneficiaries of a 
restrictive, private medical aid in SA. Hypertensive patients were 
identified by their chronic medication authorisation. All claims 
data of hypertensive patients who were registered members of the 
participating medical scheme and received either an ACEI or an ARB 
in their hypertensive treatment regimen were included. Claims data 
for 2010 and 2011 were assessed. Hypertensive patients who claimed 
<90 days for their chronic medication were excluded from the study.
All the ACEIs and ARBs that are available in SA, were identified via 
their unique National Pharmaceutical Product Index (NAPPI) codes 
as registered with the Medicines Control Council of SA.
Hypertensive patients of interest were categorised into three groups:
• ACEI group
• ARB group
• combined group (patients that received an ACEI or an ARB in 
their treatment regimens during the 2-year period under review).
Costs associated with the payment of the chronic medication were used 
as the input costs in the ‘cost-to-benefit’ health economic analysis.
The cardiovascular disorders/complications, for which hypertensive 
patients were treated during the 2-year period under review, were 
identified via The International Statistical Classification of Diseases 
and Related Health Problems, 10th Revision (ICD-10) codes. 
Costs associated with the treatment of the cardiovascular disorders/
complications during the 2-year period under review were used as the 
downstream costs in the ‘cost-to-benefit’ health economic analysis. The 
downstream costs were used as a proxy to compare the clinical efficacy 
of the two classes of drugs in preventing cardiovascular complications.
A cost-benefit analysis was performed on the claims data, comparing 
the input costs in rand (ACEIs v. ARBs as chronic medication) against 
the downstream costs (treatment of the cardiovascular disorders/
Angiotensin converting enzyme inhibitors v. 
angiotensin receptor blockers in the management 
of hypertension: A funder’s perspective
J L Makkink,1,2 MB ChB; O B W Greeff,2 MB ChB, FCFP (SA), MPharmMed, FFPM (RCP)
1  South African Police Service Medical Scheme (POLMED), Pretoria, South Africa
2  Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, South Africa
Corresponding author: J L Makkink (jacom@polmed.co.za)
Background. Hypertension poses a huge financial risk to any funder/medical aid, including the risk-mitigating strategies provided by the managed 
care organisations that are required to manage patients with hypertension. The South African Hypertension Guideline states that the choice of 
therapy – an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) – should be based on cost and tolerability. 
Objective. To assess the costs of ACEIs v. ARBs in the management of hypertensive patients and the prevention of cardiovascular 
complications for a private medical aid scheme in South Africa.
Method. A Phase IV observational, retrospective cohort study of over 480 000 beneficiaries between 2010 and 2011 was undertaken. Hypertensive 
patients were identified by their chronic medication authorisation and were categorised into three groups: ACEI, ARB and combined groups. A 
cost-benefit analysis was performed on the claims data, comparing the input costs in rand against the downstream costs using analysis of variance.
Results. Data from 28 165 patients were included in the study. Based on the health economic analysis that was performed, there was no 
statistically significant difference in the input costs between the ACEI and the ARB groups. However, a statistically significant reduction in 
the downstream costs was observed in the ACEI group v. the ARB and combined groups (p<0.0001).
Conclusion. It is more cost beneficial to treat chronic hypertensive patients with an ACEI than ARBs in preventing cardiovascular-related 
complications. It is recommended that managed care companies continue recommending ACEIs rather than ARBs in the treatment of 
hypertensive patients. 
S Afr Med J 2014;104(4):292-294. DOI:10.7196/SAMJ.7593
RESEARCH
293       April 2014, Vol. 104, No. 4
complications). Because there were many 
independent variables associated with single 
members that required analysis, an analysis 
of variance (ANOVA) model was used.
Results
Data of 28 165 patients were included. Total 
input costs and downstream costs are reflected 
in Table 1 for the ACEI, ARB and combined 
groups.
An ANOVA model was used to determine 
the statistical significance in the variances 
observed between the input costs v. the 
downstream costs in the three groups under 
review (Table 2).
When comparing the least squares means 
(LSMs) of the input costs of the ACEI group 
v. the ARB group, there was not a statistically 
significant difference between these two 
groups (p=0.24). However, when comparing 
the LSMs of the input costs of the combined 
group v. the ACEI and ARB groups, a 
statistically significant difference was 
observed (p=0.01 and p=0.05, respectively) 
(Table 3).
When comparing the LSMs of the 
downstream costs in the three groups under 
review with one another, a statistically 
significant difference was seen in all three 
instances (p<0.0001) (Fig. 1).
Discussion 
Based on our health economic analysis, there 
was not a statistically significant difference 
in the input costs between the ACEI and 
the ARB groups. However, a statistically 
significant reduction in the downstream 
costs was observed in the ACEI group v. 
the ARB and combined groups (p<0.0001). 
Patients in the combined group, that were 
treated with an ACEI and an ARB during 
the period under review, were least cost 
beneficial. A limitation of the study was that 
the groups were not stratified for baseline 
cardiovascular risk.
Table 1. Total and per patient input and downstream costs per group
ACEI ARB Combined
Patients, n
Total, N 19 901 7 029 1 235
Male 11 742 3 654 655
Female 8 159 3 375 580
Input costs (ZAR)
2010 16 256 963.95 7 944 473.21 2 705 300.80
2011 17 094 598.74 8 109 171.80 2 852 782.20
Total 33 351 562.69 16 053 645.01 5 558 083.00
Cost per patient, average
2010 816.89 1 130.24 2 190.53
2011 858.98 1 153.67 2 309.95
Downstream costs (ZAR)
2010 119 635 140.87 53 534 678.73 26 123 522.28
2011 130 263 702.72 63 763 614.29 31 269 660.78
Total 249 898 843.59 117 298 293.02 57 393 183.06
Cost per patient, average  
2010 6 011.51 7 616.26 21 152.65
2011 6 545.59 9 071.51 25 319.56
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ZAR = South African rand.
Table 2. ANOVA of downstream and input costs per group
Costs per group Cost (ZAR), LSM (±SE) p-value
ACEI
Downstream 6 278.55 (±133.19) <0.0001
Input 837.94 (±133.19) <0.0001
ARB
Downstream 8 343.88 (±224.10) <0.0001
Input 1 141.96 (±224.10) <0.0001
Combined
Downstream 23 236.11 (±534.64) <0.0001
Input 2 250.24 (±534.64) <0.0001
ANOVA = analysis of variance; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker;  
LSM = least squares mean; ZAR = South African rand; SE = standard error.
Table 3. Comparison of LSMs by data/type on downstream and input costs between groups
ACEI, p-value ARB, p-value Combined, p-value
Downstream Input Downstream Input Downstream Input 
ACEI
Downstream - <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Input <0.0001 - <0.0001 0.2435 <0.0001 <0.0104
ARB
Downstream <0.0001 <0.0001 - <0.0001 <0.0001 <0.0001
Input <0.0001 0.2435 <0.0001 - <0.0001 0.0559
Combined
Downstream <0.0001 <0.0001 <0.0001 <0.0001 - <0.0001
 Input <0.0001 0.0104 <0.0001 0.0559 <0.0001 -
LSMs = least squares means; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker.
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Conclusion
This health economic analysis reveals that it is more cost beneficial 
to treat chronic hypertensive patients with an ACEI than with ARBs 
to prevent cardiovascular-related complications. It is recommended 
that in the drug utilisation review process, managed care companies 
continue with their effort in recommending ACEIs rather than ARBs 
in the treatment of their hypertension patients. 
Acknowledgement. We thank Dr M van der Linde for his statistical support.
References
1. Council for Medical Schemes. Annual Report 2010 - 2011. Pretoria: CMS;85. http://www.medicalschemes.
com/files/Annual%20Reports/CMS-AR-2011-WEB.pdf (accessed 19 February 2014).
2. Council for Medical Schemes. Annual Report 2010 - 2011. Pretoria: CMS;81. http://www.medicalschemes.
com/files/Annual%20Reports/CMS-AR-2011-WEB.pdf (accessed 19 February 2014).
3. POLMED. Key Trends Report. January 2012;22.
4. Seedat YK, Rayner BL. South African Hypertension Guideline 2011. S Afr Med J 2012;102(1):57-84.
Accepted 18 November 2013.
Fig. 1. ANOVA of cost least squares means (LSMs) v. data source (p<0.0001). (ZAR = South African rand; ACEI = angiotensin converting enzyme inhibitor; 
ARB = angiotensin receptor blocker.)
